Statin Use and Amyotrophic Lateral Sclerosis Survival: A Population‐Based Cohort Study
European Journal of Neurology · 2025-03 · 32 (3)
DOI: 10.1111/ene.70095 ↗At a glance
Kohortenstudie in European Journal of Neurology, published online on 2025-03-04. Written by Anders Myhre Vaage and 5 co-authors. Institution: Department of Neurology, Akershus University Hospital, Lørenskog, Norway. Major MEDLINE topics: Amyotrophic Lateral Sclerosis, Hydroxymethylglutaryl-CoA Reductase Inhibitors. Cited 8 times so far (Crossref); 50 references. The full text is freely available (open access, CC BY 4.0). Funded by: ALS Norway, Helse Sør-Øst RHF.
Abstract (original language)
Background
Dyslipidemia is common in amyotrophic lateral sclerosis (ALS). Statin use has been associated with both favorable and poor prognoses. We assessed whether statin use affects ALS survival.
Methods
We linked four Norwegian health surveys (1972–2003) with mandatory national registries to obtain information on premorbid health, ALS diagnosis, and death. Using the Norwegian Prescribed Drug Registry, we identified participants who had dispensed statins pre‐ and post‐diagnosis. We first compared pre‐diagnosis statin discontinuation rates between ALS patients and matched controls. Flexible parametric models were then fitted to estimate the relationship between statin use and survival time in ALS, using restricted mean survival time and hazard ratio (HR) as effect measures.
Results
A total of 524 patients (43% female) with ALS were included. Mean time from ALS diagnosis to death or end of study was 2.0 (SD 2.1) years. A substantial proportion of statin users (21%) discontinued statins during the year leading up to diagnosis. This group was characterized by poorer ALS prognosis compared to those adhering to statins and were included as statin users in our analysis. After adjusting for sex, age, birth year, riluzole use and premorbid smoking status, body mass index, and total cholesterol levels, statin use was not associated with ALS survival. The estimated mean survival difference comparing statin users to non‐users was 0.74 (95% CI −5.98 to 7.47) months, corresponding to a HR of 0.97 (95% CI 0.77–1.23).
Conclusion
Statin use was not associated with ALS survival, suggesting that statins should not routinely be discontinued in ALS.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Neurology, Akershus University Hospital, Lørenskog, Norway.
- Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
- Department of Infection Control and Vaccines, Norwegian Institute of Public Health, Oslo, Norway.
- Department of Community Medicine and Global Health, University of Oslo, Oslo, Norway.
- Department of Physical Health and Ageing, Norwegian Institute of Public Health, Oslo, Norway.
ORCID profiles: Anders Myhre Vaage, Trygve Holmøy, Jesper Dahl, Haakon E Meyer, Ola Nakken
Funding
- ALS Norway
- Helse Sør-Øst RHF
Cite
APA
Vaage, A. M., Holmøy, T., Dahl, J., Stigum, H., Meyer, H. E., & Nakken, O. (2025). Statin Use and Amyotrophic Lateral Sclerosis Survival: A Population‐Based Cohort Study. European Journal of Neurology, 32(3). https://doi.org/10.1111/ene.70095
Vancouver
Vaage AM, Holmøy T, Dahl J, Stigum H, Meyer HE, Nakken O. Statin Use and Amyotrophic Lateral Sclerosis Survival: A Population‐Based Cohort Study. European Journal of Neurology. 2025;32(3). doi:10.1111/ene.70095
BibTeX
@article{Vaage2025,
author = {Vaage, Anders Myhre and Holmøy, Trygve and Dahl, Jesper and Stigum, Hein and Meyer, Haakon E and Nakken, Ola},
title = {Statin Use and Amyotrophic Lateral Sclerosis Survival: A Population‐Based Cohort Study},
journal = {European Journal of Neurology},
year = {2025},
volume = {32},
number = {3},
doi = {10.1111/ene.70095}
}
EUVIMED